HLA Laboratory, Children's Hospital Los Angeles, Los Angeles, CA.
Am J Transplant. 2014 Jul;14(7):1592-8. doi: 10.1111/ajt.12734. Epub 2014 Jun 16.
Multi-center kidney paired donation (KPD) is an exciting new transplant option that has not yet approached its full potential. One barrier to progress is accurate virtual crossmatching for KPD waitlists with many highly sensitized patients. Virtual crossmatch results from a large multi-center consortium, the National Kidney Registry (NKR), were analyzed to determine the effectiveness of flexible center-specific criteria for virtual crossmatching. Approximately two-thirds of the patients on the NKR waitlist are highly sensitized (>80% CPRA). These patients have antibodies against HLA-A (63%), HLA-B (66%), HLA-C (41%), HLA-DRB1 (60%), HLA-DRB3/4/5 (18-22%), HLA-DQB1 (54%) and HLA-DPB1 (26%). With donors typed for these loci before activation, 91% of virtual crossmatches accurately predicted an acceptable cell-based donor crossmatch. Failed virtual crossmatches were attributed to equivocal virtual crossmatches (46%), changes in HLA antibodies (21%), antibodies against HLA-DQA (6%), transcription errors (6%), suspected non-HLA antibodies (5%), allele-specific antibodies (1%) and unknown causes (15%). Some failed crossmatches could be prevented by modifiable factors such as more frequent assessment of HLA antibodies, DQA1 typing of donors and auditing data entry. Importantly, when transplant centers have flexibility to define crossmatch criteria, it is currently feasible to use virtual crossmatching for highly sensitized patients to reliably predict acceptable cell-based crossmatches.
多中心肾对体捐赠(KPD)是一种令人兴奋的新移植选择,但尚未充分发挥其潜力。进展的一个障碍是对具有许多高度致敏患者的 KPD 候补名单进行准确的虚拟交叉匹配。对来自大型多中心联盟国家肾脏登记处(NKR)的虚拟交叉匹配结果进行了分析,以确定针对 KPD 候补名单的灵活中心特异性虚拟交叉匹配标准的有效性。NKR 候补名单上约三分之二的患者是高度致敏的(>80%CPRA)。这些患者具有针对 HLA-A(63%)、HLA-B(66%)、HLA-C(41%)、HLA-DRB1(60%)、HLA-DRB3/4/5(18-22%)、HLA-DQB1(54%)和 HLA-DPB1(26%)的抗体。在激活前对这些基因座进行供体分型,91%的虚拟交叉匹配准确预测可接受的细胞基础供体交叉匹配。虚拟交叉匹配失败归因于不确定的虚拟交叉匹配(46%)、HLA 抗体变化(21%)、针对 HLA-DQA 的抗体(6%)、转录错误(6%)、疑似非 HLA 抗体(5%)、等位基因特异性抗体(1%)和未知原因(15%)。通过更频繁地评估 HLA 抗体、对供体进行 DQA1 分型和审核数据录入等可修改的因素,可以预防一些失败的交叉匹配。重要的是,当移植中心具有定义交叉匹配标准的灵活性时,目前可以使用虚拟交叉匹配对高度致敏的患者进行可靠的可接受的细胞基础交叉匹配预测。